Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update / 中华男科学杂志
National Journal of Andrology
; (12): 651-656, 2014.
Article
em Zh
| WPRIM
| ID: wpr-309659
Biblioteca responsável:
WPRO
ABSTRACT
Medication has become the first-line option for the management of lower urinary tract symptoms induced by benign prostatic hyperplasia (LUTS/BPH) for its advantages in controlling the symptoms, inhibiting BPH progression, and reducing serious complications and surgical risks. Recent years have witnessed remarkable achievement in the studies of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of LUTS/BPH. PDE5-Is can effectively alleviate LUTS/BPH, with even better efficacy when combined with al-ARAs.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Hiperplasia Prostática
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Inibidores da Fosfodiesterase 5
/
Sintomas do Trato Urinário Inferior
Limite:
Humans
/
Male
Idioma:
Zh
Revista:
National Journal of Andrology
Ano de publicação:
2014
Tipo de documento:
Article